Pulse Biosciences, Inc. (PLSE) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$73M, a net margin of -20794.6%; the best year in this period was 2016 with -$10M.
Over the twelve months to September 30, 2026, revenue was $1M and net income -$84M.
Free cash flow was -$54M in fiscal 2025 and positive in 0 of the 10 years shown.
The diluted share count rose 512% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $350000 | $0 | $0 | $700000 | $1M | $0 | — | — | — | — |
| Gross profit | $400000 | -$189000 | $0 | $0 | -$11M | -$550000 | $0 | — | — | — | — |
| Operating income | -$87M | -$77M | -$56M | -$44M | -$58M | -$63M | -$50M | -$48M | -$38M | -$26M | -$10M |
| Net income | -$84M | -$73M | -$54M | -$42M | -$59M | -$64M | -$50M | -$47M | -$38M | -$26M | -$10M |
| EPS (diluted) | $-1.21 | $-1.08 | $-0.92 | $-0.85 | $-1.72 | $-2.28 | $-2.14 | $-2.26 | $-2.20 | $-1.73 | $-0.86 |
| R&D | $57M | $45M | $32M | $28M | $21M | $29M | $26M | $25M | $17M | $10M | $6M |
| Revenue growth | — | — | — | −100.0% | −50.6% | — | — | — | — | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$63M | -$54M | -$36M | -$33M | -$47M | -$54M | -$35M | -$34M | -$24M | -$11M | -$8M |
| Capital spending | -$370000 | -$315000 | -$125000 | -$121000 | -$401000 | -$437000 | -$441000 | -$608000 | -$276000 | -$3M | -$64000 |
| Free cash flow | -$64M | -$54M | -$36M | -$33M | -$47M | -$55M | -$36M | -$35M | -$24M | -$14M | -$8M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $17M | $21M | $14M | $7M | $5M | $15M | $10M | $11M | $12M | $11M | $870000 |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $81M | $118M | $44M | $61M | $29M | $20M | $7M | $51M | $3M | $16M |
| Debt | — | $8M | $9M | $9M | $76M | $11M | $11M | $7M | — | — | — |
| Equity | — | $81M | $115M | $44M | -$2M | $36M | $23M | $31M | $66M | $46M | $25M |
| Total assets | — | $95M | $132M | $59M | $78M | $54M | $41M | $42M | $71M | $50M | $26M |
| Shares (diluted) | 69M | 67M | 58M | 50M | 34M | 28M | 23M | 21M | 17M | 15M | 11M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 26.8% | -54.0% | — | — | -1606.3% | -38.8% | — | — | — | — | — |
| Operating margin | -5821.1% | -21982.6% | — | — | -8293.9% | -4443.9% | — | — | — | — | — |
| Net margin | -5603.9% | -20794.6% | — | — | -8357.9% | -4489.4% | — | — | — | — | — |
| FCF margin | -4263.9% | -15553.4% | — | — | -6773.4% | -3845.8% | — | — | — | — | — |
| ROIC | — | -87.2% | -45.5% | -81.4% | -78.8% | -134.2% | -145.9% | -101.1% | -44.7% | -43.9% | -29.7% |
| ROE | — | -90.2% | -46.7% | -95.2% | 2602.5% | -178.4% | -217.8% | -152.8% | -56.6% | -55.6% | -37.6% |
Frequently asked questions
What is Pulse Biosciences’s annual revenue?
$350000 in fiscal 2025 and $1M over the twelve months to September 30, 2026.
How much profit does Pulse Biosciences make?
Net income was -$73M in fiscal 2025 (net margin -20794.6%).
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.